Skip to content

Nuvalent, Inc. NUVL Net Change in Cash

Net Change in Cash at other companies

Pfizer logo
PfizerPFE
$563M+50.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$117.04M+241%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$118.75M-211%
Exelixis logo
ExelixisEXEL
-$256.34M-662%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$57.19M+127%
Incyte logo
IncyteINCY
$363.28M+43.1%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s net change in cash?
Nuvalent, Inc. (NUVL) reported net change in cash of -$102.01M in Q1 2026.
How has Nuvalent, Inc.'s net change in cash changed year-over-year?
Nuvalent, Inc.'s net change in cash decreased by 310.4% year-over-year, from -$24.86M to -$102.01M.
What is the long-term trend for Nuvalent, Inc.'s net change in cash?
Over 3 years (2022 to 2025), Nuvalent, Inc.'s net change in cash has grown at a -12.5% compound annual growth rate (CAGR), from $173.28M to $116.05M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.